Logo
x

Search

Subscribe Now

adc

ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in EU and Select International Territories

ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in E...

  • July 8, 2022
ADC Entered an Exclusive License Agreement with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Japan

ADC Entered an Exclusive License Agreement with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta (loncas...

  • January 18, 2022
PharmaShots Weekly Snapshots (October 25 - 29, 2021)

PharmaShots Weekly Snapshots (October 25 - 29, 2021)

  • October 29, 2021
ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

  • October 29, 2021
PharmaShots Interview: Pyxis Oncology's Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio

PharmaShots Interview: Pyxis Oncology's Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Fu...

  • April 26, 2021
Synaffix Expands its Existing Collaboration with ADC Therapeutics to Explore Two Additional Programs

Synaffix Expands its Existing Collaboration with ADC Therapeutics to Explore Two Additional Programs

  • July 24, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.